RegRapPod: InConversation
RegRapPod: InConversation
Podcast Description
RegRapPod: InConversation is the podcast series of the TOPRA member's journal Regulatory Rapporteur. If you'd like to appear as a guest on the podcast, or otherwise contribute to the journal, please email [email protected].
Podcast Insights
Content Themes
The podcast explores themes surrounding regulatory affairs in the pharmaceutical industry, with episodes focusing on electronic product information (ePI), sustainability in pharmaceuticals, career paths into regulatory roles, and the challenges posed by Identification of Medicinal Products (IDMP) requirements.
RegRapPod: InConversation is the podcast series of the TOPRA member’s journal Regulatory Rapporteur.
If you’d like to appear as a guest on the podcast, or otherwise contribute to the journal, please email [email protected].
InConversationtalks about conditional marketing authorisation − and how the work starts after approval – with Catherine Moncad
Conditional marketing authorisation (CMA) can help bring innovative medicines to patients with high unmet medical need sooner. But for sponsors, particularly emerging biotechs and first-time marketing authorisation holders, approval is only the beginning.
In this latest episode of the RegRapPod − InConversation series, Regulatory Rapporteur Managing Editor Claire McDermott speaks with Catherine Moncad, Vice President of Regulatory Services at TMC Pharma Services Ltd, about the realities of planning for, securing and maintaining a conditional marketing authorisation in the EU.
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.